PACIRA BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments
PACIRA BIOSCIENCES, INC. (PCRX) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments of $0 for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-01.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments · last filed 2018-11-01
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2018-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2018-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2018-03-31 was $0.00.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2017-09-30 was -$2.00K.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-03 | ||
| 2017-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$517.00K derived: sum of 2 quarters · filed 2018-11-01 | -$126.33M 10-Q · filed 2018-11-01 |
| 2017-06-30 | -$515.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$126.33M 10-Q · filed 2018-08-02 | |
| 2017-03-31 | -$125.81M 10-Q · filed 2018-05-03 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $0.00 10-Q · filed 2017-08-02 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |